Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (2016 - 2025)

Cytosorbents' Shares Outstanding history spans 15 years, with the latest figure at $62.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $62.8 million for Q4 2025, up 14.54% from a year ago — trailing twelve months through Dec 2025 was $62.8 million (up 14.54% YoY), and the annual figure for FY2025 was $62.8 million, up 14.54%.
  • Shares Outstanding for Q4 2025 was $62.8 million at Cytosorbents, roughly flat from $62.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $62.8 million in Q4 2025 to a low of $43.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $44.3 million (2023), against an average of $50.2 million.
  • The sharpest move saw Shares Outstanding increased 0.36% in 2022, then rose 24.3% in 2023.
  • Year by year, Shares Outstanding stood at $43.5 million in 2021, then rose by 0.36% to $43.6 million in 2022, then increased by 24.3% to $54.2 million in 2023, then rose by 1.09% to $54.8 million in 2024, then rose by 14.54% to $62.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $62.8 million, $62.8 million, and $62.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.